Class / Patent application number | Description | Number of patent applications / Date published |
514513000 | C-C(=X)-X-C containing (X is chalcogen and at least one X is other than oxygen) | 16 |
20080300303 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents - The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according to formula (I) for the treatment of diseases associated with increased glycolytic metabolism. In one embodiment, the disease is a fungal infection. | 12-04-2008 |
20090005445 | Article comprising calcium for reducing the production of TSST-1 - Articles comprising one or more calcium salts are provided. The articles can contain one or more calcium salts in an amount effective to reduce the production of TSST-1 by at least about 50% when measured by the Shake Flask Method. In certain embodiments, the one or more calcium salts can be substantially non-lethal to | 01-01-2009 |
20100152289 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD - There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods which is represented by formula (I): | 06-17-2010 |
20110196034 | Green garlic and methods of production - A new vegetable, referred to herein as green garlic, grown from garlic bulbils is disclosed. In particular examples, the green garlic is rich in one or more thiosulfinates. Methods of producing green garlic are also disclosed. In some examples, such methods permit year-round commercial production of green garlic. | 08-11-2011 |
20120115946 | Formulation - The present invention relates to a hygroscopic matrix based formulation, a process for the preparation thereof and its use in the treatment of diseases. | 05-10-2012 |
20120270938 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN - A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and | 10-25-2012 |
20130143962 | Adamantyl Derivatives as Therapeutic Agents - The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis. | 06-06-2013 |
20130225680 | COMPOUND, COMPOSITION AND USES THEREOF - The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications. | 08-29-2013 |
20140005261 | RACECADOTRIL LIQUID COMPOSITIONS | 01-02-2014 |
20140005262 | RACECADOTRIL LIPID COMPOSTIONS | 01-02-2014 |
20140171502 | New Process - The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl] 2-methylthiopropionate which is useful as a pharmaceutically active compound. | 06-19-2014 |
20140221476 | COMPOUND, COMPOSITION AND USES THEREOF - The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications. | 08-07-2014 |
20140275246 | RACECADOTRIL LIPID COMPOSITIONS - A lipid composition comprising racecadotril, at least one surfactant and a lipid. | 09-18-2014 |
20140336254 | Small Molecules That Covalently Modify Transthyretin - A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and | 11-13-2014 |
20140364493 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION - The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory activity as an active ingredient. | 12-11-2014 |
20150133544 | ETHYL (2R)-2-ACETAMIDO-3-(4-METHYLBENZOYLSULFANYL)PROPANOATE AND USES THEREOF - A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction. | 05-14-2015 |